Mathias Schmid
Papers
1
Total Citations
32
H-Index
1
About
Mathias Schmid is a leading clinical researcher in urothelial carcinoma, with a primary focus on perioperative chemoimmunotherapy for muscle-invasive bladder cancer. His major contribution lies in pioneering the integration of immune checkpoint inhibitors with standard cisplatin-based chemotherapy in the neoadjuvant setting. As the principal investigator of the SAKK 06/17 phase II trial, Schmid demonstrated the safety and efficacy of combining durvalumab with cisplatin/gemcitabine before surgery for operable muscle-invasive urothelial carcinoma (MIUC). His work addresses a critical unmet need, as relapse rates remain high even after standard neoadjuvant chemotherapy and surgery. The preplanned interim analysis of this trial, which has garnered 32 citations, provides compelling evidence that chemoimmunotherapy is a feasible and promising approach to improve outcomes for these high-risk patients. Schmid’s research is at the forefront of translating immunotherapy advances from the metastatic setting into earlier, potentially curative treatment paradigms, directly impacting clinical practice and shaping future trial designs in genitourinary oncology.
Research Focus
Key Achievements
Top Papers
- 1